NO20072692L - Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8 - Google Patents

Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8

Info

Publication number
NO20072692L
NO20072692L NO20072692A NO20072692A NO20072692L NO 20072692 L NO20072692 L NO 20072692L NO 20072692 A NO20072692 A NO 20072692A NO 20072692 A NO20072692 A NO 20072692A NO 20072692 L NO20072692 L NO 20072692L
Authority
NO
Norway
Prior art keywords
interfering nucleic
preparations
methods
nucleic acid
short interfering
Prior art date
Application number
NO20072692A
Other languages
English (en)
Norwegian (no)
Inventor
John Hunter
Sameer Goregaoker
Tony Priestley
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO20072692L publication Critical patent/NO20072692L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20072692A 2004-10-27 2007-05-25 Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8 NO20072692L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62248404P 2004-10-27 2004-10-27
PCT/US2005/038792 WO2006047687A2 (en) 2004-10-27 2005-10-26 Compositions and methods for short interfering nucleic acid inhibition of nav1.8

Publications (1)

Publication Number Publication Date
NO20072692L true NO20072692L (no) 2007-05-25

Family

ID=36061603

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072692A NO20072692L (no) 2004-10-27 2007-05-25 Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8

Country Status (14)

Country Link
US (4) US7786291B2 (ja)
EP (2) EP2371954A1 (ja)
JP (3) JP2008517629A (ja)
KR (1) KR20070083828A (ja)
CN (2) CN102352355A (ja)
AR (1) AR051829A1 (ja)
AU (1) AU2005299310A1 (ja)
CA (1) CA2584785A1 (ja)
IL (1) IL182680A0 (ja)
MX (1) MX2007005069A (ja)
NO (1) NO20072692L (ja)
SG (1) SG158921A1 (ja)
WO (1) WO2006047687A2 (ja)
ZA (1) ZA200703453B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942948A4 (en) * 2005-11-04 2010-03-03 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE
US8183221B2 (en) 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
MX2011000080A (es) 2008-06-30 2011-03-02 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de pirimidina sustituidos.
PE20141682A1 (es) * 2011-10-26 2014-11-14 Pfizer Ltd Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
TWI516593B (zh) * 2012-06-11 2016-01-11 義守大學 一種聚核苷酸用以製備減緩疼痛藥物之用途
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EP3294398A4 (en) * 2015-05-11 2019-01-09 Alcyone Lifesciences, Inc. SYSTEMS AND METHODS FOR DRUG DELIVERY
CA3045135A1 (en) 2016-12-21 2018-06-28 Alcyone Lifesciences, Inc. Drug delivery systems and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513180D0 (en) 1995-06-28 1995-08-30 Univ London Ion channel
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU2001245793A1 (en) * 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
DK1309726T4 (en) * 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
CZ308053B6 (cs) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
GB0120238D0 (en) * 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
WO2004087956A2 (en) * 2003-04-02 2004-10-14 Ionix Pharmaceuticals Limited Cell lines for the functional expression of nav1.8
WO2005014782A2 (en) * 2003-06-13 2005-02-17 Alnylam Europe Ag., Double-stranded ribonucleic acid with increased effectiveness in an organism
US7341835B2 (en) * 2004-01-13 2008-03-11 Affymetrix, Inc. Methods of analysis of alternative splicing in mouse

Also Published As

Publication number Publication date
AU2005299310A1 (en) 2006-05-04
SG158921A1 (en) 2010-02-26
WO2006047687A2 (en) 2006-05-04
EP2371954A1 (en) 2011-10-05
CN102352355A (zh) 2012-02-15
EP1809745A2 (en) 2007-07-25
US20100305192A1 (en) 2010-12-02
US20060199779A1 (en) 2006-09-07
ZA200703453B (en) 2008-06-25
CN101103112B (zh) 2011-11-16
US20140256787A1 (en) 2014-09-11
US8729045B2 (en) 2014-05-20
JP2008517629A (ja) 2008-05-29
MX2007005069A (es) 2007-06-25
JP2013176386A (ja) 2013-09-09
WO2006047687A3 (en) 2006-07-06
JP2011015695A (ja) 2011-01-27
KR20070083828A (ko) 2007-08-24
US20130109739A1 (en) 2013-05-02
IL182680A0 (en) 2007-09-20
US7786291B2 (en) 2010-08-31
US8309703B2 (en) 2012-11-13
AR051829A1 (es) 2007-02-14
CN101103112A (zh) 2008-01-09
CA2584785A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
NO20072692L (no) Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8
Cai et al. PROTON GRADIENT REGULATION 3 recognizes multiple targets with limited similarity and mediates translation and RNA stabilization in plastids
BRPI0413521A (pt) seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares
EA200801942A1 (ru) Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
ATE494370T1 (de) Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren
WO2005117991A3 (en) Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
WO2020198509A3 (en) Modified oligonucleotides with increased stability
ATE513910T1 (de) Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren
EP1828219A4 (en) ARNSI SILENCE OF APOLIPOPROTEIN B
WO2006131599A3 (en) Method of profiling a cell population
WO2006110599A3 (en) Cacna1e in cancer diagnosis, detection and treatment
BRPI0410876A (pt) molécula inibidora do complemento, anticorpo, proteìna de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteìna de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um aninal desenvolva uma doença ou um disturbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteìna de fusão ou uma molécula de ácido nucleico
WO2007030560A3 (en) Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
WO2005042692A3 (en) A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
BRPI0411103A (pt) método, métodos de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo, e de tratamento de uma doença autoimune, e, produto
BRPI0415302A (pt) uso de polimorfismos genéticos que se associam a eficácia de tratamento de doença inflamatória
WO2008054341A3 (en) Method of bioimaging using nanocrystals of fluorescent dyes
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
Reiber et al. The expression of selected non-ribosomal peptide synthetases in Aspergillus fumigatus is controlled by the availability of free iron
WO2004022782A3 (en) Compositions and methods for tissue specific or inducible inhibition of gene expression
WO2005089426A3 (en) Method of treating sepsis
WO2001088124A3 (en) Method and reagent for the inhibition of erg
ATE486127T1 (de) Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung
Weatherly et al. Intermediate-depth circulation in the Gulf of Mexico estimated from direct measurements
WO2008144351A3 (en) Compositions and methods for inhibiting inducible t cell kinase (itk) and treating asthma and bronchial inflammations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application